Prosecution Insights

Browse Companies Examiners Firms Draft Your Response

Last updated: August 18, 2026

Examiner: KAUFMAN, CLAIRE M

Tech Center 1600 • Art Units: 1646 1674

This examiner grants 63% of resolved cases

Performance Statistics

63.3%

Allow Rate

+3.3% vs TC avg

611

Total Applications

+51.5%

Interview Lift

1086

Avg Prosecution Days

Based on 567 resolved cases, 2023–2026

Rejection Statute Breakdown

3.3%

§101 Eligibility

17.1%

§102 Novelty

25.6%

§103 Obviousness

39.8%

§112 Clarity

Currently Pending Office Actions

App #	Title	Status	Assignee
17416403	METHOD OF TREATING CANCER USING A HISTONE ACETYLTRANSERACE ACTIVATOR WITH IFN¿ AND AN IMMUNE CHECKPOINT INHIBITOR	Non-Final OA	The Regents of the University of California
18392954	ANTIBODY MOLECULES TO PG-L1 AND METHODS OF TREATING CANCER AND INFECTIOUS DISEASES	Final Rejection	PRESIDENT AND FELLOWS OF HARVARD COLLEGE
18175225	METHOD OF TREATMENT OF PATIENTS HAVING REDUCED SENSITIVITY TO A BCL-2 INHIBITOR	Non-Final OA	The Regents of the University of Colorado, A Body Corporate
18035470	CD19 BINDING MOLECULES AND USES THEREOF	Non-Final OA	NOVARTIS AG
18666545	CCR8 ANTIBODIES FOR THERAPEUTIC APPLICATIONS	Final Rejection	Bayer Aktiengesellschaft
18666512	CCR8 ANTIBODIES FOR THERAPEUTIC APPLICATIONS	Final Rejection	Bayer Aktiengesellschaft
17817033	MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137	Final Rejection	BioNTech SE
18019612	COMBINED MEDICATION FOR TREATING SOFT TISSUE SARCOMA	Non-Final OA	CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy